AffiAB® Goat polyclonal antibody specifically targets SARS-CoV-2's NSP7, providing an effective immunological response. With high specificity and sensitivity, the antibody is a reliable choice for research and clinical diagnostic applications.
The AffiAB® Goat anti-NSP7 (SARS-CoV-2) Polyclonal IgG Antibody is an antibody specifically designed to target and detect the NSP7 protein of the SARS-CoV-2 virus. NSP7, also known as non-structural protein 7, is one of the key non-structural proteins encoded by the viral RNA of SARS-CoV-2.
This polyclonal antibody is generated by immunizing goats with purified NSP7 protein or a specific peptide sequence derived from NSP7. The resulting antibody is then purified from goat serum using various techniques to ensure high specificity and quality.
The AffiAB® Goat anti-NSP7 (SARS-CoV-2) Polyclonal IgG Antibody is widely used in research and diagnostic applications to study the SARS-CoV-2 virus. It can be utilized in techniques such as Western blotting, immunohistochemistry, immunofluorescence, and ELISA to detect and analyze the expression and localization of NSP7 in infected cells or patient samples.
By specifically targeting NSP7, this antibody allows researchers to investigate the function and role of this protein in the viral replication cycle and pathogenesis of SARS-CoV-2. NSP7 is known to interact with other viral proteins and form complexes that are crucial for viral replication and transcription.
Understanding NSP7 is important for deciphering the molecular mechanisms of viral replication, identifying potential drug targets, and developing antiviral therapies against SARS-CoV-2. The AffiAB® Goat anti-NSP7 (SARS-CoV-2) Polyclonal IgG Antibody provides a valuable tool for researchers studying the SARS-CoV-2 virus and its non-structural proteins, contributing to advancements in virology, immunology, and COVID-19 research.